Abstract
Atrial fibrillation (AF) is the most common type of arrhythmia, its estimated prevalence is between 1 and 4% of general population and a vast majority of AF patients are over 65-years-old. Age and comorbidities predispose to higher risk of both ischeamic stroke and bleeding, while AF itself increases the risk of ischaemic stroke 5-fold. At the same time discontinuation of oral anticoagulants is often observed among elderly patients, mainly due to their comorbidities and treatment complications. However, presently available stroke prevention methods, pharmaceuticals and dosing regimens allow effective and feasible treatment even in the most demanding patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
